#6 - CRSPR (NASDAQ:CRSP)
When you think of disruptive technology, the field of gene editing may be more of what you imagine. It’s a tantalizing field. But it’s not a particularly new field. It’s just that many companies have been working in relative obscurity.
That could be changing. And if it does, CRSPR Therapeutics (NASDAQ:CRSP) is a stock that needs to be in your portfolio. The company pioneered its proprietary CRISPR/Cas9 gene editing platform. The platform is designed to make directed changes to genomic DNA.
To date, the company has not brought a product to market. But the company’s partnership with Vertex Pharmaceuticals, Incorporated (NASDAQ:VRTX) may change that. The two companies are working together to bring CRSPR’s CTX110 candidate through clinical trials. If successful, it could be a mulit-billion opportunity.
And the opportunities can multiply, particularly if the company is successful at delivering gene editing solutions for rare genetic disorders and, perhaps, even finding a treatment for certain cancers.
About CRISPR Therapeutics
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
More- Current Price
- $42.22
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 11 Buy Ratings, 8 Hold Ratings, 1 Sell Ratings.
- Consensus Price Target
- $77.59 (83.8% Upside)
